Seroprevalence of HBV among people living with HIV in Anyigba, Kogi State, Nigeria

Cornelius Arome Omatola1, Joshua Idofe1, Martin-Luther Oseni Okolo1, Patience Omebije Adejo1, Mesach Maunta Maina2, Joseph Abraham Oyiguh3

1. Department of Microbiology, Kogi State University, Anyigba, P.M.B.1008, Kogi State, Nigeria.
2. Department of Veterinary Microbiology and Parasitology, University of Maiduguri, Borno State, Nigeria.
3. Department of Science Laboratory Technology, Federal Polytechnic Idah, Kogi State, Nigeria.

Abstract

Background: Co-infection of HBV with HIV is associated with significant morbidity and mortality globally. In spite of increasing reports of HIV/HBV co-morbidities in Nigeria, little or no data exists on this subject in Anyigba. Therefore, we determined the prevalence of hepatitis B surface antigenemia among HIV positive patients on anti-retroviral treatment programme in Anyigba, Kogi State, North-Central Nigeria.

Methods: Sera samples obtained from 200 consented HIV patients were screened for HBsAg using the commercial rapid test membrane-based qualitative immunoassay. A structured questionnaire was used to collect information on patients’ demographic variables and probable risk factors for HBV transmission.

Results: Overall, 3.5% of HIV patients were seropositive to HBsAg and the difference between seroprevalence rates and patients’ age as well as gender was not statistically significant (p>0.05). There was significant difference between patients’ demographic variables such as marital status (p=0.013) and educational level (p=0.004) and HBsAg seropositivity. Patients with a history of surgical applications (p=0.01) and who indulged in alcoholism (p=0.03) significantly had higher rates of concomitant HIV/HBV infection in the study area.

Conclusion: Our findings underscore the importance of routine screening for HBV in the HIV infected populations especially in developing countries where the infection is endemic. We advocate for public enlightenment programmes on routes of virus acquisitions with a view to reduce the morbidity and mortality associated HIV/HBV co-infection.

Keywords: HBV, HIV, co-infection, risk factors, Nigeria.

DOI: https://dx.doi.org/10.4314/ahs.v19i2.17

Cite as: Omatola CA, Idofe J, Okolo M-LO, Adejo PO, Maina MM, Oyiguh JA. Sero-prevalence of HBV among people living with HIV in Anyigba, Kogi State, Nigeria. Afr Health Sci. 2019;19(2):1938-1946. https://dx.doi.org/10.4314/ahs.v19i2.17

Introduction

Hepatitis B virus (HBV) is the most prevalent etiology of viral inflammation of the human liver1. Globally, more than 2 billion people are infected with Hepatitis B virus2-3, with approximately 360 million people being HBV carriers4. sub-Saharan Africa alone has over 8% of the HBV carriers rate5-6. Nigeria is one of the countries in sub-Saharan Africa with high burden of HBV infection7. World Health Organization in8 defines low prevalence as <2%, moderate prevalence as 2-8% and high prevalence as >8% HBsAg positivity. Approximately 13.6% of the total Nigerian populations are chronic carriers of HBV7. The risk of contracting HBV in Nigeria, a country with approximately 20,000 HBsAg seropositivity rate, is wide-ranging and reasons have been attributed to low compliance with HBV vaccination and high exposure through unprotected sexual intercourse, blood transfusion and perinatal transmission9.

Hepatitis B virus is a highly infectious agent that causes both acute and chronic infections across the globe10 with prolonged forms often incriminated in liver cirrhosis and hepatocellular carcinoma11 and about 600,000 deaths annually12. HBV is 50 - 100 times more infectious than
HIV and 10 times more infectious than hepatitis C virus (HCV)\(^\text{13}\). Common practices such as use of toothbrush or razor blade can easily predispose one to HBV infection due to the low infectious dose of the virus\(^\text{13}\). Majority of childhood infection results in chronic carriers of the virus while infection in adolescents/adults which usually occurs via sexual contact, contaminated needles, and less often from transfusion of blood products, usually resolves unless the individual is immunocompromised (e.g. HIV/AIDS patients)\(^\text{14}\). Patients with chronic disease usually do not present with symptoms; however, cirrhosis and liver cancer may eventually develop\(^\text{15}\).

HBV coinfected is one of the frequent complications in HIV positive patients\(^\text{16}\) and due to the shared routes of transmission; the incidence rate of coinfection with both viruses is on the increase\(^\text{17}\). HIV/HBV co-morbidity has been identified as the one of the major factors that accelerates the progression of HIV disease\(^\text{18}\) and individuals coinfected with both viruses have been shown to be 17 times more likely at risk for death from complications of liver disease than those monoinfected with HBV\(^\text{19}\). Previous studies has documented HBV protein X that enhances the replication of HIV-1\(^\text{20}\) while HIV decreases the rate of HBsAg clearance in acute infection and enhances the progression of liver disease in those with chronic hepatitis B\(^\text{21}\). With the introduction of HAART in both industrialized and developing countries, the incidence of AIDS-related opportunistic infections have decreased while liver disease resulting from chronic infection with HBV and HCV has emerged leading causes of morbidity and mortality in HIV-infected patients\(^\text{22-25}\). This is as a result of decreased response to HBV treatment which in turn raises the risk of hepatotoxicity of HAART and drug interactions\(^\text{26}\). The interaction of HBV and HIV therapies can lead to additional complexities due to increase potential for the selection of drug-resistant mutations\(^\text{26}\).

Epidemiological studies have shown that the seroprevalence of HBV/HIV co-infection vary from 5 to 10% in the USA to 20-30% in parts of sub-Saharan Africa and Asia\(^\text{12}\). In Nigeria, HIV/HBV co-infection rate is estimated to be within 10% and 70%\(^\text{26}\). Study on HIV/HBV co-infection is important as it will help to compliment the epidemiological data on the two viruses in Nigeria which in turn would provide information on the variation in the prevalence of HIV/HBV co-infection rate\(^\text{6}\). In Anyigba, Kogi State, Nigeria, there is currently no documented report on HBV/HIV co-infection to the best of our knowledge. In light of this background, it becomes crucial to determine the prevalence of HBV/HIV in Anyigba which will complement the epidemiological data on the two viruses in Nigeria and will in turn influence policy making as well as prevention and treatment strategies for HBV/HIV co-infection particularly in view of the implications of using HAART with anti-HBV potency.

**Materials and methods**

**Study area**

This study was conducted in Anyigba, a city in Kogi State, found in the North Central region of Nigeria. Anyigba which lies between latitude 7°01′-7°02′ north and longitude 7°11′-7°32′ east, has an average altitude of 420m above sea level\(^\text{27}\). Behavioral practices such as early age at first sexual intercourse, use of unscreened blood and blood products, scarification marks, promiscuity and intravenous drug use are common among the inhabitants.

**Study population**

This was a hospital-based cross-sectional study in which 200 consenting HIV positive patients on Highly Active Anti-retroviral Therapy (HAART) at the Grimard Hospital and Maria Goretti Hospital between January and April, 2017 were recruited using a non-probability convenient sampling technique. These hospitals run a weekly HIV/AIDS clinic and are the most utilized health facilities in the study area with a record of approximately 2000 HIV patients per year. Trained medical personnel in each hospital clearly explained the objectives/benefits of the study to the patients and only those who gave consent by completing and endorsing filled-in questionnaires were consecutively recruited. Consentig attendees, male or female, aged 5 years and above who provided written informed consent were eligible for participation in the study. Ethical approval for the study was obtained from the hospital management board on health issues in accordance with the code of conduct for biomedical research involving human subjects (Ethical clearance no:058).
Sample collection and storage
Two (2) ml of blood sample was aseptically collected from each of the 200 consenting HIV positive patients by vein-puncture into a well labeled non-anticoagulant tube. Information concerning patients’ demographic profile and associated risk factors were also obtained by means of structured questionnaires. Blood sample obtained from each patient was centrifuged at 3000rpm for 8-10 seconds to separate sera from whole blood. Sera samples were stored at -20°C in line with the manufacturer’s instruction until screened for HBsAg.

Assays for HBsAg
A one step test was carried out to detect HBsAg in serum using Coschesic strips®. This method is immuno-chromatographic and qualitative in nature and detects HBV antigen in human blood. The test strip which is coated with the mouse monoclonal anti-HBs capture antibody has more than 99.9% sensitivity and 98.6% specificity when read in-vitro. The test and interpretation of the results were done in accordance with the guidelines of the kit’s manufacturers.

Data analysis
Sample size (N) was determined using formula N = Zα2pq /d2 where: Zα = standard normal deviate set at 1.96, corresponding to 95% confidence level; p = prevalence, q=1-p and d = degree of precision set at 0.05 (95% confidence interval). Assuming a prevalence of 14% based on the most recent HBsAg prevalence from a similar study28, q=86% (0.86) and N =185 which was approximated to the nearest hundred as 200. Data generated from the study was analyzed using the statistical packages for social sciences (SPSS version 16.0). Descriptive data was presented as simple summaries in statistical tables. Chi square test was used to establish differences between participants’ variables and prevalence rates. A p-value 0.05 was set as level of statistical significance.

Results
Table 1 shows the socio-demographic data and outcome of HBsAg test among HIV patients in Anyigba. Seven (3.5%) of the 200 HIV patients in this study tested positive to HBsAg with the highest prevalence rate (13.3%) in patients that were aged ≥ 51. Sixty one males and 139 females participated in this study, out of which 2(3.27%) males and 5(3.59%) females respectively were positive to HBsAg. Though the number of participated females were twice that of the males, the difference between gender and HBV infection was not statistically significant (p>0.05). Marital status related seroprevalence showed higher HBV prevalence (20%) among HIV patients who were widowed compared to those who were single (9.09%) and married (1.39%) and the difference between HBV infection and marital status was statistically significant (p<0.05). Educationally, patients with primary and no formal education had significantly higher hepatitis B surface antigenemia rate (37.0%) compared to those with secondary (4.2%) and tertiary (1.2%) levels of education. Table 2 depicts the possible predisposing factors of HBV infection. History of surgery and high rate of alcohol consumption were significantly related to HBV infection (p<0.05). Other factors such as poor knowledge of HBV infection, history of intravenous drug use, multiple sexual partners, mouth-to-mouth kissing, history of blood transfusion were also noted with higher HBsAg seroprevalence rates although, the difference between each variable and HBsAg seropositivity was not statistically significant (p>0.05).
| Variable               | No tested | No (%) positive | P-value |
|-----------------------|-----------|-----------------|---------|
| **Age range**         |           |                 |         |
| 5-20                  | 25        | 1(4.0)          |         |
| 21-30                 | 66        | 2(3.0)          |         |
| 31-40                 | 42        | 1(12.4)         | 0.30    |
| 41-50                 | 52        | 1(1.9)          |         |
| 51-59                 | 15        | 2(13.3)         |         |
| **Gender**            |           |                 |         |
| Male                  | 61        | 2(3.27)         |         |
| Female                | 139       | 5(3.59)         | 0.91    |
| **Marital status**    |           |                 |         |
| Single                | 36        | 3(9.09)         |         |
| Married               | 146       | 2(1.39)         | 0.013   |
| Divorced              | 6         | 0(0.00)         |         |
| Widowed               | 12        | 2(20.00)        |         |
| **Highest qualification** |       |                 |         |
| None                  | 4         | 1(25.0)         |         |
| Primary               | 25        | 3(12.0)         |         |
| Secondary             | 24        | 1(4.2)          | 0.005   |
| Tertiary              | 147       | 2(1.2)          |         |
| **Occupation**        |           |                 |         |
| Business woman        | 12        | 1(8.33)         |         |
| Students              | 34        | 2(5.88)         |         |
| House wives           | 67        | 2(2.99)         | 0.85    |
| Civil servants        | 76        | 2(2.63)         |         |
| Farmers               | 5         | 0(0.00)         |         |
| Unemployed            | 6         | 0(0.00)         |         |
Discussion

In HBV endemic countries, the severity of HBV infection has been classified into low (<2%), moderate (2-8%) and high (>8%) prevalence by WHO. An overall 3.5% HBsAg seropositivity was observed in this study, thus suggesting a moderate prevalence of HBV infection among HIV patients undergoing anti-retroviral therapy in Anyigba, Kogi State, Nigeria. HBsAg seropositivity rate of 3.5% in the population of HIV patients in this region calls for great concern as HBV/HIV co-morbidity have been linked with high risk of mother–to-child transmission and accelerated progression of HIV infection. Findings in this study is comparable to the 3.6% reported in Biu, Borno State, Nigeria. It is also similar to the 3.6% by Smit et al., 3.2% by Rai et al., 3% by Lodenyo et al. and 3.7% by de Almeida et al. previously reported among HIV patients in Netherlands, Japan, Johannesburg and Brazil respectively. Lower prevalence of 2.7%, 1.2%, 1.13%, 1.8%, and 2.6% was earlier reported among HIV positive patients in Nigeria, Tanzania, Mali, Iran and New York respectively. Okonko et al. also reported 2.5% HBV/HIV coinfection among apparently healthy blood donors in Ibadan, Nigeria. The seroprevalence rate in our study is however lower than the prevalence of HBV/HIV co-infection range of 10-70% earlier reported for Nigeria. This lower prevalence rate is likely due to the efforts of the public health agencies on HIV/AIDS prevention in the Country since measures aimed at preventing HIV infection also protect against HBV which shares similar transmission routes with HIV.

| Variable                          | No. tested | No Positive | P-value |
|-----------------------------------|------------|-------------|---------|
| 1. Knowledge of HBV               |            |             |         |
| Yes                               | 73         | 1(1.37)     | 0.21    |
| No                                | 127        | 6(4.72)     |         |
| 2. Mouth-To-Mouth Kissing         |            |             |         |
| Yes                               | 142        | 5(3.52)     | 0.98    |
| No                                | 58         | 2(3.44)     |         |
| 3. Shared Sharp Objects           |            |             |         |
| Yes                               | 125        | 3(2.40)     | 0.52    |
| No                                | 75         | 4(5.33)     |         |
| 4. History of Circumcision        |            |             |         |
| Yes                               | 61         | 2(3.28)     | 0.91    |
| No                                | 139        | 5(3.60)     |         |
| 5. No of Sexual Partners          |            |             |         |
| One                               | 25         | 1(4.00)     |         |
| Two                               | 55         | 1(1.82)     | 0.73    |
| Two                               | 120        |             | 5 (4.17)|
| 6. History of STDs                |            |             |         |
| Yes                               | 73         | 2(2.74)     | 0.66    |
| No                                | 127        | 5(3.94)     |         |
| 7. Use of Condom                  |            |             |         |
| Regular                           | 52         | 3(5.77)     |         |
| Occasional                        | 76         | 2(2.63)     | 0.91    |
| Never                             | 72         | 2(2.78)     |         |
| 8. Had Blood Transfusion          |            |             |         |
| Yes                               | 28         | 1(3.57)     | 0.98    |
| No                                | 172        | 6(3.49)     |         |
| 9. History of Surgery             |            |             |         |
| Yes                               | 25         | 3(12.00)    | 0.01    |
| No                                | 175        | 4(2.29)     |         |
| 10. History of IDU                |            |             |         |
| Yes                               | 7          | 1(14.29)    | 0.11    |
| No                                | 193        | 6(3.11)     |         |
| 11. Immunized For HBV             |            |             |         |
| Yes                               | 68         | 3(4.11)     | 0.62    |
| No                                | 132        | 4(3.03)     |         |
| 12. Tribal Marks                  |            |             |         |
| Yes                               | 33         | 1(3.03)     | 0.87    |
| No                                | 167        | 6(3.59)     |         |
| 13. Alcohol Consumption Rate      |            |             |         |
| Low                               | 162        | 3(1.85)     |         |
| Moderate                          | 31         | 3(9.68)     | 0.03    |
| High                              | 7          | 1(14.29)    |         |
that both male and female were apparently equal in exposure to HBV. Previous studies reported similar findings. The higher ratio of females to male (2.3:1) in this study may be attributed to the fact that more females than males’ visits hospitals for medical attention in Nigeria, a reason previously reported.

The significantly higher HBsAg seropositivity rate in HIV patients who were aged ≥50 was also reported among cohort of HIV patients in Nassarawa State, Nigeria. Reason for the age of peak infection in this study could be attributed to increased parenthood responsibility as patients within this age group constitute economically productive years in the Nigerian workforce. Unsafe sexual behavior of the polygamous men coupled with their religious inclination, socio-economic, cultural and occupation of the men as was previously opined by Bello et al., in the northern Nigeria could be possible explanation for the observed prevalence.

Analysis by marital status showed that the widowed patients significantly had higher HBsAg prevalence and reason could be attributed to absence of family cover which could shield or restrain them from having multiple sexual partners. This significant association of marital status with HBV infection is in conformity with previous reports of Sule et al. in Kogi State, Sirisena et al. in Plateau State, Ezegbudo et al. in Anambra State and Mohammed et al. in Kanu State.

Educational related HBsAg seroprevalence revealed higher HBV infection in HIV patients with primary/no formal education compared to those with secondary and tertiary levels of education and there was a significant difference between patient’s educational status and HBsAg seropositivity (p<0.05). The steady decrease in prevalence observed in present study may be a reflection of the fact that educated individuals are likely more enlightened on the dangers posed by hepatitis B when seropositive to HIV and as such could implement strategies in preventing HBV infection. This may be evident from the lower prevalence of HBsAg (1.37%) in patients with prior knowledge of HBV infection compared to those without previous knowledge (4.72%). This finding supports the assertion that prevalence rates of infections such as HIV, HBV and HIV/HBV co-infection were inversely associated with educational status. Finding from present study was also previously corroborated by reports of Sule et al. in Ankpa and Mehmet et al. in the Southeastern region of Turkey. Efforts geared towards improving the level of education to reduce poverty and improve the quality of life of these vulnerable communities should therefore be considered in order to achieve a breakthrough in the fight against HIV/HBV co-morbidity in Nigeria.

The significantly higher hepatitis B surface antigenemia rate in patients with history of surgical application is similar with previous reports in Ethiopia and Benue State, Nigeria. Practices such as use of poorly unsterilized instruments during surgical procedures as previously opined by Uwaezuoke et al. could be responsible for the significantly higher antigenemia among patients with such history. The strong association between alcohol consumption and HBV infection (P=0.00) in this study is in conformity with previous report of Ndako et al., but contradicts finding of Mbaawuaga et al. People who consume high rate of alcohol are likely more promiscuous and the fact that they may also fail to protect themselves through correct and consistent condom use could be a possible explanation for the higher predisposition to concomitants HIV/HBV infection.

Limitations

The seroprevalence in the current study may reflect the true burden of disease in the study area, since only hospital-based cases were considered. Also, findings from the present study might not be generalizable to the entire country, as it showed to be at variance with some published studies from other parts of Nigeria. Despite these limitations, this study provides baseline seroprevalence data on HBV/HIV co-morbidity for future studies.

Conclusion

The results of this study showed that HBV/HIV co-infection is endemic amongst HIV positive patients in Anyigba, Kogi State, North Central Nigeria. Considering the impact of antiretroviral on the progression of HBV, we recommend that all recently diagnosed HIV cases be screened for HBV as this will improve management of HBV/HIV co-infection. The high prevalence of HBV infection in patients with no knowledge of HBV infection underscores the need for continuous public health education on ways of avoiding risky behaviors such as alcoholism and unprotected sexual intercourse.
Conflict of interest
None declared.

References
1. Arababadi MK, Pourfathollah AA, Jafarzadeh A, Hassanshahi G, Rezvani ME. Association of exon 9 but not intron 8 VDR polymorphisms with occult HBV infection in south-eastern Iranian patients. J Gastroenterol Hepatol. 2009; 25 (1): 90-3.
2. Zhu R, Zhang H, Yu H, Li H, Ling YQ, et al. Hepatitis B virus mutations associated with in situ expression of hepatitis B core antigen, viral load and prognosis in chronic hepatitis B patients. Path. Res. and Pract. 2008; 204: 731-742.
3. Li W, Miao X, Qi Z, Zeng W, Liang J. et al. Hepatitis B virus X protein upregulates HSP90 alpha expression via activation of c-Myc in human hepatocarcinoma cell line, HepG2. Virology Journal. 2010; 7: 45.
4. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012; 142(6):1264–1273
5. United Nations Programme on HIV/AIDS (UNAIDS). The Gap Report. ISBN: 978-92-9253-062-4, 2014. [Accessed on 12 July 2015]
6. Williams R. Global challenges in liver disease. Hepatology. 2006; 44(3):521–526.
7. Zampino R, Boemio A, Sagnelli C, Alessio L, Adinolfi LE, et al. Hepatitis B virus burden in developing countries. World J. Gastroenterol. 2015; 21(42): 11941-11953.
8. World Health Organisation (WHO). Prevalence of hepatitis virus in the world by country http://www.who.int/csr/disease/hepatitis/en/. 2010. Date accessed online (June, 2011).
9. Musa BM, Bussell S, Borodo MM, Samaila AA, Femi OL. Prevalence of Hepatitis B Virus Infection in Nigeria, 2000-2013: A Systematic Review and Meta-analysis. Nigerian J. of Clin. Prac. 2015; 18(2): 163-172.
10. Thomas HC. Viral Hepatitis (4th ed.). Hoboken: Wiley. 2013; p. 83.ISBN9781118637302
11. Karimi-Googheri M, Daneshvar H, Nosratabadi R, Zare-Bidaki M, Hassanshahi G, et al. Important roles played by TGFbeta in hepatitis B infection. J Med Virol, 2014; 86 (1): 102-8.
12. World Health Organization (WHO). Hepatitis B Fact sheet N0 204. Available; http://www.who.int/csr/disease/hepatitis. 2009. The prevalence of hepatitis B surface antigenaemia in patients with human immunodeficiency virus (HIV) infection in Gombe, Nigeria. Annals of African Medicine. 2004;3(1):10 –12.
13. Elgouhari HM, Tamimi TIAR, Carey WD. Hepatitis B virus infection:Understanding its epidemiology, cause and diagnosis. Cleveland J. Med. 2008;75:881-889. PubMed
14. Punngiapong S, Kim WR, Poterucha JJ. Natural History of Hepatitis B Virus Infection: an Update for Clinicians. Mayo Clinic Proceedings; 2007; 82(8): 967–975.
15. Chang MH. Hepatitis B virus infection. Foetal Neonatal Med. 2007; 12:160-167.
16. Askari A,Hakimi H, Ahmadabadi BN, Hassanshahi G, Arababadi MK. Prevalence of Hepatitis B Co-Infection among HIV Positive Patients: Narrative Review Article. Iranian J. Publ. Health. 2014; 43(6) 705-712.
17. Chen JJ, Yu CB, Du WB, Li LJ. Prevalence of hepatitis B and C in HIV-infected patients: a meta-analysis. Hepatobiliary & Pancreatic Diseases International. 2011; 10(2): 122-7.
18. Ikpeme EE, Etukudo OM, and Ekrikpo UE. Sero-prevalence of HBV and HIV co-infection in children and outcomes following highly active antiretroviral therapy (HAART) in Uyo, South-South Nigeria. Afr. Health Sci. 2013; 13(4):955-961. PubMed
19. Thio CL, Seaberg EC, Skolasky R. Dangers of HIV/hepatitis B infection. Lancet, 2002;360: 1921 – 1926.
20. Gomez-Gonzalo M, Carretero M, Rullas J, Lara-Pezzi E, Aramburu J, et al. The hepatitis B virus X protein induces HIV-1 replication and transcription in synergy with T-cells activation signals. Biol. Chem. 2001; 276:35435-35443. PubMed
21. Thio CL. Hepatitis B virus infection in HIV-infected persons. Current hepatitis report. 2004;3:91- 97.
22. Fix OK, Lacarnini SA, Peters MG. Virology and clinical management of hepatitis B and HIV coinfection. The PRN Notebook. 2007; 11(4): 20-27. PubMed
23. Lewden C, Salmon D, Morlat P, Bevilacqua S, Jougla E, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J. Epidemiol. 2005;34:121-130. PubMed
24. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, et al. Mortality in the highly active antiretroviral era: changing causes of death and disease in the HIV outpatient study. J. Acquir. Immune Defic. Syndr. 2006; 43:27-34. PubMed
25. Thio CL. Hepatitis B and Human Immunodeficiency Virus Coinfection. Hepatology. 2009; 49(5):S138-S145.
26. Owolabi LF, Ibrahim A, Musa BM, Gwaram BA, Dutse AI, et al. Prevalence and burden of human immunodeficiency virus and hepatitis B virus coinfection in Nigeria: a systematic review and meta analysis. J AIDS Clin Res. 2014; 5:308
27. Ifatimehin OO, Musa SD, Adeyemi JD. An analysis of the changing land use and its impact on the environment of Anyigba Town, Nigeria. J Sustain. Dev. Afr., 2009; 10(4):357-364.
28. Sule WF, Okonko IO, Yumusa IP, Odu NN, Frank-Peterside N. Hepatitis B surface antigen (HBsAg) and risk factors of transmission among patients attending hospital in Ankpa, Kogi State, Nigeria. Nature and Sci. 2011; 9:37-41.
29. Bello RH, Olabode HOK. Human immunodeficiency virus (HIV) and hepatitis B virus (HBV): the favourable effect of lamivudine, as part of combined antiretroviral therapy, on HBV: hepatitis-B virus (HBV). The favourable effect of lamivudine, as part of combined antiretroviral therapy, on HBV. J Int Assoc Physicians AIDS Care (Chic). 2009; 8 (1): 47-51.
30. Moradi A, Khodabakhshi B, Sadeghipour M, Behtarat S, Tabarreai A. Concurrent infections of hepatitis C and HIV in hepatitis B patients in the northeast of Iran. Tropical doctor, 41 (3): 129-31.
31. Rai RR, Mathur A, Mathur D, Udawat HP, Nepalia S, et al. Prevalence of occult hepatitis B & C in HIV patients infected through sexual transmission. Trop Gastroenterol, 2007; 28 (1):19-23.
32. Lodenyio H, Schoub B, Ally R, Kairu S, Segal I. Hepatitis B and C virus infections and liver function in AIDS patients at Chris Hani Baragwanath Hospital, Johannesburg. East Afr. Med. J. 2000; 77 (1): 13-5.
33. de-Almeida Pereira RA, Mussi AD, de Azevedoe Silva VC, Souto FJ. Hepatitis B Virus infection in HIV-positive population in Brazil: results of a survey in the state of Mato Grosso and a comparative analysis with other regions of Brazil. BMC Infect Dis. 2006; 6 (34): 34.
34. Mbawuwa EM, Christian UI, Anthony CI, Godwin TAJ. Studies on prevalence, co-infection and associated risk Factors of hepatitis B virus (HBV) and human Immunodeficiency virus (HIV) in Benue State, Nigeria. Sci. J. of Public Health. 2014; 2(6): 569-576.
35. Telatela SP, Matee MI, Munubhi EK. Seroprevalence of hepatitis B and C viral coinfections among children infected with human immunodeficiency virus attending the paediatric HIV care and treatment center at Muhimbili National Hospital in Dar-es-Salaam, Tanzania. BMC Public Health. 2007;7:338-343. PubMed
36. Tounkara A, Sarro YS, Kristensen S, Dao S, Diallo H, et al. Seroprevalence of HIV/HBV coinfection in Malian blood donors. J Int Assoc Physicians AIDS Care (Chic). 2009; 8 (1): 47-51.
37. Moradi A, Khodabakhshi B, Sadeghipour M, Behtarat S, Tabarreai A (2011). Concurrent infections of hepatitis C and HIV in hepatitis B patients in the northeast of Iran. Tropical doctor, 41 (3): 129-31.
38. Toussi ST, Abadi J, Roseenberg M, Levanon D. Prevalence of hepatitis B and C infections in children infected with HIV. Clin. Infect. Dis. 2007; 45:795-798. PubMed
39. Okonko IO, Okentuguba PO, Akinpelu AO. Prevalence of HBsAG among Attendees of Reproductive Family and Health (ARFH) center in Ibadan, Southwestern Nigeria. American-Eurasian J. of Sc. Res. 2012; 7(3):100-105. PubMed
40. Sule WF, Okonko IO, Ebuthe AJ, Donbraye E, Fadeyi A et al. Farming and Non-Farming Individuals Attending Grimard Catholic Hospital, Anyigba, Kogi State, Nigeria were Comparable in Hepatitis B Surface Antigen Seroprevalence. Current Res. J. of Biol. Sc. 2010; 2(4): 278-282.
41. Omotola CA, Onoja BA, Thomas T. High rate of Hepatitis B surface antigenaemia among people living with HIV/AIDS in Kakuri, Kaduna State, Nigeria. Viral Immunology. 2017;30(7)516-521. PubMed
42. Mustapha SK, Jibrin YB. The prevalence of hepatitis B surface antigenaemia in patients with human immunodeficiency virus (HIV) infection in Gombe, Nigeria. Annals of African Medicine. 2004;3(1):10 – 12.
43. Donbraye E, Japhet MO, Adesina AO, Abayomi OA. Prevalence of asymptomatic hepatitis B virus surface antigenaemia in children in Ilesha, Osun state, south-Western Nigeria. Afr J Micro Res. 2014; 8(23): 2329-2331.
44. Terwase JM, Emeka CK. Prevalence of Hepatitis B Surface Antigen among Residents of Julius Berger Staff Quarters, Kubwa,Abuja. International Journal of Prevention and Treatment. 2015; 4(2): 29-33.
45. Uneke CJ, Ogbe O, Inyama PU, Anyanwu GI, Njoku MO et al. Prevalence of hepatitis B surface antigen among blood donors and human immunodeficiency virus-infected patients in Jos, Nigeria. Mem. Inst. Oswaldo. Cruz Rio de Janeiro. 2005; 100:13-16. PubMed
46. Ishaku A, Godwin O, Ishaleku D. Seroprevalence of hepatitis B and C co-infection among cohort seropositive HIV patients accessing healthcare in Nassarawa State North Central, Nigeria. British J. of psychol Res. 2013; 1(1):15-24. PubMed
47. Sirisena ND, Njoku MO, Idoko JA. Hepatitis B surface Antigenaemia in patients with Human Immunodeficiency Virus-1 infection in Jos, Nigeria. *Nigerian Med. Pract.* 2002; 41: 18-20.

48. Ezegbudo CN, Agbonlahor DE, Nwobu GO, Igwe CU, Agba MI et al. The seroprevalence of hepatitis B surface antigen and human immunodeficiency virus among pregnant women in Anambra state, Nigeria. Dept. of Int. Med. Shiraz E-Medical J 2004; 5(2): 1-8.

49. Mohammed Y, Sharif A, Dabo NT. Seroprevalence of HBsAg Among Patients with Febrile Illnesses in Murtala Muhammad Specialist Hospital, Kano, Nigeria. *Bayero J. of Pure and Applied Sc.* 2015; 8(1): 19 –23.

50. Mehmet D, Meliksah E, Serif Y, Gunay S, Tuncer O, et al. Prevalence of Hepatitis B infection in the southeastern region of Turkey: Comparison of risk factors for HBV infection in rural and urban areas. *J. of Infect. Dis.* 2005;58:15-19.

51. Zenebe Y, Mulu W, Yimer M, Adera B. Sero-prevalence and risk factors of hepatitis B virus and human immunodeficiency virus infection among pregnant women in Bahir Dar city, Northwest Ethiopia: a cross sectional study. *BMC Infect. Dis.*, 2014, 14:118.

52. Uwaezuoke SN, Nnli RO. Death of a G-6-P-D deficient child with co-morbid HIV infection linked to scarification. *J Trop Paediatr.* 2007;53:62-3. PubMed

53. Ndako JA, Echeonwu GON, Nwankiti OO, Onovoh, EM. Hepatitis B virus seroprevalence among pregnant females in Northern Nigeria. *Res. J. of Med. Sci.* 2012; 6(3):129-133. PubMed